SCHEMBL20993453

SCHEMBL20993453

COC(=O)N1CCC(Cl)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.45
GAA P10253 1/20 0.44
CHRNB2 P17787 2/20 0.44
CHRNA4 P43681 2/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
BRD4 O60885 2/20 0.43
BRDT Q58F21 1/20 0.43
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.40
HPGD P15428 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3065995 0.85 EPHX1 (0.45) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL5271075 0.83 SMN1; SMN2 (0.62) GAASMN1; SMN2L3MBTL1TSHR
SCHEMBL3498368 0.83 LMNA (0.55) EPHX1GAASMN1; SMN2BRD4L3MBTL1
SCHEMBL12436920 0.83 GAA (0.46) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL771850 0.82 GAA (0.53) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL29589464 0.82 EPHX1 (0.45) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL6495220 0.82 EPHX1 (0.45) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL5188810 0.81 GAA (0.68) GAASMN1; SMN2TSHRHPGD
SCHEMBL7773725 0.81 GAA (0.44) EPHX1GAACHRNB2CHRNA4CHRNB4
SCHEMBL18697087 0.80 EPHX1 (0.44) EPHX1GAACHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119400-A1 QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2022-04-21 US disclosed
US-11248000-B2 Quinazoline and indole compounds to treat medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2022-02-15 US disclosed
EP-3448389-B1 QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2021-09-29 EP disclosed
US-10961252-B2 Quinazoline and indole compounds to treat medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2021-03-30 US disclosed
US-20200165262-A1 Quinazoline and Indole Compounds to Treat Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2020-05-28 US disclosed
US-20190135825-A1 Quinazoline and Indole Compounds to Treat Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248000-B2 Quinazoline and indole compounds to treat medical disorders CFB, TFPI, MAOB EPHX1 1989/4885GAA 2512/4885CHRNB2 1299/4885
US-20220119400-A1 QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS CFB, TFPI, MAOB EPHX1 1989/4885GAA 2512/4885CHRNB2 1299/4885
US-10961252-B2 Quinazoline and indole compounds to treat medical disorders CFB, TFPI, MAOB EPHX1 1989/4885GAA 2512/4885CHRNB2 1299/4885
US-20200165262-A1 Quinazoline and Indole Compounds to Treat Medical Disorders CFB, TFPI, MAOB EPHX1 1989/4885GAA 2512/4885CHRNB2 1299/4885
US-20190135825-A1 Quinazoline and Indole Compounds to Treat Medical Disorders CFB, TFPI, MAOB EPHX1 1989/4885GAA 2512/4885CHRNB2 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.